Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 6:16:52.
doi: 10.1186/s12886-016-0225-1.

Worldwide Argus II implantation: recommendations to optimize patient outcomes

Affiliations
Review

Worldwide Argus II implantation: recommendations to optimize patient outcomes

Devon H Ghodasra et al. BMC Ophthalmol. .

Erratum in

  • Erratum to: Worldwide Argus II implantation: recommendations to optimize patient outcomes.
    Ghodasra DH, Chen A, Arevalo JF, Birch DG, Branham K, Coley B, Dagnelie G, de Juan E, Devenyi RG, Dorn JD, Fisher A, Geruschat DR, Gregori NZ, Greenberg RJ, Hahn P, Ho AC, Howson A, Huang SS, Iezzi R, Khan N, Lam BL, Lim JI, Locke KG, Markowitz M, Ripley AM, Rankin M, Schimitzek H, Tripp F, Weiland JD, Yan J, Zacks DN, Jayasundera KT. Ghodasra DH, et al. BMC Ophthalmol. 2016 Jul 29;16(1):129. doi: 10.1186/s12886-016-0259-4. BMC Ophthalmol. 2016. PMID: 27473341 Free PMC article. No abstract available.

Abstract

Background: A position paper based on the collective experiences of Argus II Retinal Prosthesis System investigators to review strategies to optimize outcomes in patients with retinitis pigmentosa undergoing retinal prosthesis implantation.

Methods: Retinal surgeons, device programmers, and rehabilitation specialists from Europe, Canada, Middle East, and the United States were convened to the first international Argus II Investigator Meeting held in Ann Arbor, MI in March 2015. The recommendations from the collective experiences were collected. Factors associated with successful outcomes were determined.

Results: Factors leading to successful outcomes begin with appropriate patient selection, expectation counseling, and preoperative retinal assessment. Challenges to surgical implantation include presence of staphyloma and inadequate Tenon's capsule or conjunctiva. Modified surgical technique may reduce risks of complications such as hypotony and conjunctival erosion. Rehabilitation efforts and correlation with validated outcome measures following implantation are critical.

Conclusions: Bringing together Argus II investigators allowed the identification of strategies to optimize patient outcomes. Establishing an on-line collaborative network will foster coordinated research efforts to advance outcome assessment and rehabilitation strategies.

PubMed Disclaimer

References

    1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795–1809. doi: 10.1016/S0140-6736(06)69740-7. - DOI - PubMed
    1. Daiger SP, Sullivan LS, Bowne SJ. RetNet: Retinal Information Network. 2015. https://sph.uth.edu/retnet/. Accessed 26 Jul 2015.
    1. Food and Drug Administration. FDA approves first retinal implant for adults with rare genetic eye disease. FDA News Release. 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm339824.htm. Accessed 26 Jul 2015.
    1. da Cruz L, Coley BF, Dorn J, et al. The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss. Br J Ophthalmol. 2013;97(5):632–636. doi: 10.1136/bjophthalmol-2012-301525. - DOI - PMC - PubMed
    1. Kotecha A, Zhong J, Stewart D, da Cruz L. The Argus II prosthesis facilitates reaching and grasping tasks: a case series. BMC Ophthalmol. 2014;14(71):1–8. - PMC - PubMed